Hinge Health/$HNGE
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Hinge Health
Hinge Health Inc is a technology platform for individuals seeking to treat and prevent joint and muscle pain. Through a combination of AI-powered motion tracking technology, the Company's platform helps members address chronic musculoskeletal (MSK) conditions, enables improved member outcomes and supports cost reductions for its clients.
- Ticker
- $HNGE
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 1,437
- Headquarters
- San Francisco, United States
- Website
- www.hingehealth.com
Hinge Health Metrics
BasicAdvanced
$9.2B
85.63
$1.34
-
-
Price and volume
Market cap
$9.2B
52-week high
$117.55
52-week low
$30.08
Average daily volume
1.8M
Financial strength
Current ratio
1.336
Quick ratio
1.069
Long term debt to equity
0.005
Total debt to equity
0.017
Profitability
EBITDA (TTM)
93.56
Gross margin (TTM)
84.54%
Net profit margin (TTM)
15.15%
Operating margin (TTM)
12.75%
Effective tax rate (TTM)
1.69%
Revenue per employee (TTM)
$500,000
Management effectiveness
Return on assets (TTM)
7.70%
Return on equity (TTM)
30.38%
Valuation
Price to earnings (TTM)
85.631
Price to revenue (TTM)
12.523
Price to book
26.63
Price to tangible book (TTM)
32.45
Price to free cash flow (TTM)
31.76
Free cash flow yield (TTM)
3.15%
Free cash flow per share (TTM)
3.599
Growth
Revenue change (TTM)
49.76%
Earnings per share change (TTM)
-106.86%
What the Analysts think about Hinge Health
Analyst ratings (Buy, Hold, Sell) for Hinge Health stock.
Analyst projections of the future price of Hinge Health stock.
Bulls say / Bears say
Second-quarter revenue rose 53% and trailing-twelve-month billings grew 52%; Hinge also raised its 2026 revenue outlook to about $858 million, signalling strong demand and continued execution. (Hinge Health)
Profitability and cash generation are scaling alongside growth: Q2 non-GAAP operating income rose 136% and free cash flow almost tripled year on year to $100 million. (Hinge Health)
Hinge is extending its employer sales platform into other conditions: its migraine programme had reached 450 clients and five million covered lives by Q2, while the Cylinder deal opens a route into digestive care. (The Motley Fool, Healthcare Dive)
The shares have risen sharply, and recent analysis describes the valuation as demanding; that leaves less room for error if growth or member conversion slows. (Seeking Alpha, Simply Wall St)
Cylinder adds a new business to integrate, but is expected to contribute only $7–8 million in 2026 and currently operates at a loss; investment could weigh on margins before the planned broader rollout. (Finviz, Healthcare Dive)
Growth depends on members engaging and renewing, and on health-plan partners that distribute the service. Hinge’s latest quarterly filing warns that weaker member retention or partners directing business to competitors could harm results. (Last10K)
Data summarised monthly by Lightyear AI. Last updated on 27 Oct 2026.
Hinge Health Financial Performance
Revenues and expenses
Hinge Health Earnings Performance
Company profitability
Upcoming events
No upcoming events
Hinge Health News
AllArticlesVideos
Funds containing Hinge Health
Fund name | Fund size | $HNGE weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.17% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.17% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $3.2B | 0.06% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | $3.2B | 0.06% |
iShares MSCI World Small Cap£WLDS | $9B | 0.05% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.